U.S. Markets closed

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.98-0.05 (-1.24%)
At close: 4:00PM EDT
People also watch
CTICARRYCRISEXELCLDX
Full screen
Previous Close4.03
Open4.04
Bid3.50 x 1000
Ask5.35 x 100
Day's Range3.91 - 4.10
52 Week Range3.20 - 7.49
Volume1,354,198
Avg. Volume989,560
Market Cap394.5M
Beta2.59
PE Ratio (TTM)-3.14
EPS (TTM)-1.27
Earnings DateJul 26, 2017 - Jul 31, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.95
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting

    Study conducted in individuals who had previously received current standard of care LONDON , June 21, 2017 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today will be presenting new results from a clinical study ...

  • PR Newswire3 days ago

    Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant

    LEXINGTON, Mass., June 21, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that GlaxoSmithKline's shingles vaccine candidate, Shingrix, containing Agenus' proprietary immune adjuvant, QS-21 Stimulon®, triggered a strong immune response in elderly patients previously treated with the current vaccine, Zostavax®, for the prevention of shingles.

  • PR Newswire3 days ago

    Agenus to Webcast Annual Meeting of Stockholders

    LEXINGTON, Mass., June 21, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, June 28, 2017. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. A live webcast will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts.